CLDX — Celldex Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 744218 ·
Last close
$30.85
Market Cap
$2.42B
52W High
$35.79
52W Low
$27.92
ADV30
771,575
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 15,000 | — | -84,435,000 | -78,685,000 | 511,254,000 | 35,729,000 | 55,028,000 |
| Dec 2025 | 121,000 | — | -87,153,000 | -81,317,000 | 582,983,000 | 28,871,000 | 55,818,000 |
| Sep 2025 | 0 | — | -73,617,000 | -67,044,000 | 648,439,000 | 36,037,000 | 50,076,000 |
| Jun 2025 | 730,000 | — | -63,857,000 | -56,600,000 | 692,407,000 | 23,044,000 | 37,001,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-210,945,000
Investing CF
$209,072,000
Financing CF
$2,388,000
CapEx
$-2,714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.89
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,813,981,000
Inventory
—
Receivables
$2,015,000
ST Investments
$489,702,000
EBIT TTM
$-287,366,000
Pretax Income TTM
$-258,757,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$865,000
EBITDA
$-305,696,000
Free Cash Flow
$-126,271,376
Enterprise Value
$1,962,511,360
Total Cash
$451,457,984
Total Debt
$1,908,000
Shares Out
78,492,072
Trailing EPS
$-4.27
Book Value
$6.85
ROE
-48.9%
ROA
-30.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,545,000 | -287,367,000 | -258,757,000 | 582,983,000 | 55,818,000 | — | -210,945,000 |
| Dec 2024 | 7,020,000 | -195,078,000 | -157,863,000 | 792,340,000 | 45,335,000 | — | -157,778,000 |
| Dec 2023 | 6,883,000 | -142,042,000 | -141,429,000 | 465,627,000 | 36,456,000 | — | -107,291,000 |
| Dec 2022 | 2,357,000 | -107,096,000 | -112,325,000 | 352,735,000 | 26,531,000 | — | -103,732,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEOG | NEOGEN CORP | $1.99B | $9.14 | — |
| NTLA | Intellia Therapeutics, Inc. | $1.76B | $12.61 | — |
| NNNN | Anbio Biotechnology | $1.45B | $33.01 | — |
| LNTH | Lantheus Holdings, Inc. | $6.51B | $100.06 | — |
| ABSI | Absci Corp | $823.18M | $5.28 | — |
News headlines (Yahoo Finance, 1h cache)
[Latest] Global Cholera Vaccine Market Size/Share Worth USD 649 Million by 2035 at a 7.6 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, V
2026-05-19 04:30 · Yahoo
Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Pullback And Mixed Signals
2026-05-12 22:17 · Yahoo
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 21:55 · Yahoo
Celldex Reports First Quarter Financial Results and Provides Corporate Update
2026-05-07 20:01 · Yahoo
Innoviva (INVA) Tops Q1 Earnings Estimates
2026-05-07 01:45 · Yahoo
Wall Street Analysts See a 76.42% Upside in Celldex (CLDX): Can the Stock Really Move This High?
2026-05-04 13:55 · Yahoo
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump
2026-04-25 21:07 · Yahoo
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment
2026-04-15 07:33 · Yahoo
Celldex to Present at Upcoming Investor Conference
2026-04-13 20:01 · Yahoo
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-04-06 14:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.